Cencora, Inc.
Cencora, Inc. (COR) Stock Competitors & Peer Comparison
See (COR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| COR | $349.00 | -1.03% | 68.1B | 41.95 | $8.34 | +0.65% |
| MCK | $949.39 | +0.53% | 116.1B | 27.15 | $34.66 | +0.34% |
| CAH | $218.39 | -0.32% | 51.1B | 31.17 | $6.96 | +0.94% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $74.63 | -0.45% | 8.9B | 23.11 | $3.27 | N/A |
| PBH | $61.50 | -0.65% | 3B | 16.20 | $3.79 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +1.66% |
| GRDN | $32.59 | -2.04% | 2.1B | 47.85 | $0.68 | N/A |
| OMI | $2.68 | +8.94% | 207.1M | -0.47 | -$5.69 | N/A |
| ACH | $2.44 | +3.18% | 182M | -1.78 | -$1.34 | N/A |
Stock Comparison
COR vs MCK Comparison March 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 68.1B. In comparison, MCK has a market cap of 116.1B. Regarding current trading prices, COR is priced at $349.00, while MCK trades at $949.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 41.95, whereas MCK's P/E ratio is 27.15. In terms of profitability, COR's ROE is +1.01%, compared to MCK's ROE of -2.45%. Regarding short-term risk, COR is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check MCK's competition here
COR vs CAH Comparison March 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 68.1B. In comparison, CAH has a market cap of 51.1B. Regarding current trading prices, COR is priced at $349.00, while CAH trades at $218.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 41.95, whereas CAH's P/E ratio is 31.17. In terms of profitability, COR's ROE is +1.01%, compared to CAH's ROE of -0.59%. Regarding short-term risk, COR is more volatile compared to CAH. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check CAH's competition here
COR vs ABC Comparison March 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 68.1B. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, COR is priced at $349.00, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 41.95, whereas ABC's P/E ratio is 21.92. In terms of profitability, COR's ROE is +1.01%, compared to ABC's ROE of +1.01%. Regarding short-term risk, COR is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check ABC's competition here
COR vs HSIC Comparison March 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 68.1B. In comparison, HSIC has a market cap of 8.9B. Regarding current trading prices, COR is priced at $349.00, while HSIC trades at $74.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 41.95, whereas HSIC's P/E ratio is 23.11. In terms of profitability, COR's ROE is +1.01%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, COR is less volatile compared to HSIC. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check HSIC's competition here
COR vs PBH Comparison March 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 68.1B. In comparison, PBH has a market cap of 3B. Regarding current trading prices, COR is priced at $349.00, while PBH trades at $61.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 41.95, whereas PBH's P/E ratio is 16.20. In terms of profitability, COR's ROE is +1.01%, compared to PBH's ROE of +0.10%. Regarding short-term risk, COR is more volatile compared to PBH. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check PBH's competition here
COR vs PDCO Comparison March 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 68.1B. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, COR is priced at $349.00, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 41.95, whereas PDCO's P/E ratio is 20.48. In terms of profitability, COR's ROE is +1.01%, compared to PDCO's ROE of +0.06%. Regarding short-term risk, COR is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check PDCO's competition here
COR vs GRDN Comparison March 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 68.1B. In comparison, GRDN has a market cap of 2.1B. Regarding current trading prices, COR is priced at $349.00, while GRDN trades at $32.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 41.95, whereas GRDN's P/E ratio is 47.85. In terms of profitability, COR's ROE is +1.01%, compared to GRDN's ROE of +0.27%. Regarding short-term risk, COR is less volatile compared to GRDN. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check GRDN's competition here
COR vs OMI Comparison March 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 68.1B. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, COR is priced at $349.00, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 41.95, whereas OMI's P/E ratio is -0.47. In terms of profitability, COR's ROE is +1.01%, compared to OMI's ROE of +7.33%. Regarding short-term risk, COR is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check OMI's competition here
COR vs ACH Comparison March 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 68.1B. In comparison, ACH has a market cap of 182M. Regarding current trading prices, COR is priced at $349.00, while ACH trades at $2.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 41.95, whereas ACH's P/E ratio is -1.78. In terms of profitability, COR's ROE is +1.01%, compared to ACH's ROE of +7.33%. Regarding short-term risk, COR is less volatile compared to ACH. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check ACH's competition here
COR vs GEG Comparison March 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 68.1B. In comparison, GEG has a market cap of 56.3M. Regarding current trading prices, COR is priced at $349.00, while GEG trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 41.95, whereas GEG's P/E ratio is -4.16. In terms of profitability, COR's ROE is +1.01%, compared to GEG's ROE of -0.21%. Regarding short-term risk, COR is less volatile compared to GEG. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check GEG's competition here
COR vs HX Comparison March 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 68.1B. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, COR is priced at $349.00, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 41.95, whereas HX's P/E ratio is -1.84. In terms of profitability, COR's ROE is +1.01%, compared to HX's ROE of -1.07%. Regarding short-term risk, COR is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check HX's competition here
COR vs RDGT Comparison March 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 68.1B. In comparison, RDGT has a market cap of 12.5M. Regarding current trading prices, COR is priced at $349.00, while RDGT trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 41.95, whereas RDGT's P/E ratio is -8.19. In terms of profitability, COR's ROE is +1.01%, compared to RDGT's ROE of +0.40%. Regarding short-term risk, COR is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check RDGT's competition here
COR vs SNYR Comparison March 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 68.1B. In comparison, SNYR has a market cap of 12.1M. Regarding current trading prices, COR is priced at $349.00, while SNYR trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 41.95, whereas SNYR's P/E ratio is 4.82. In terms of profitability, COR's ROE is +1.01%, compared to SNYR's ROE of -0.20%. Regarding short-term risk, COR is less volatile compared to SNYR. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check SNYR's competition here
COR vs WGRX Comparison March 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 68.1B. In comparison, WGRX has a market cap of 11.4M. Regarding current trading prices, COR is priced at $349.00, while WGRX trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 41.95, whereas WGRX's P/E ratio is -0.13. In terms of profitability, COR's ROE is +1.01%, compared to WGRX's ROE of -15.47%. Regarding short-term risk, COR is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check WGRX's competition here
COR vs ZYXI Comparison March 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 68.1B. In comparison, ZYXI has a market cap of 1.8M. Regarding current trading prices, COR is priced at $349.00, while ZYXI trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 41.95, whereas ZYXI's P/E ratio is -0.02. In terms of profitability, COR's ROE is +1.01%, compared to ZYXI's ROE of -18.07%. Regarding short-term risk, COR is less volatile compared to ZYXI. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check ZYXI's competition here
COR vs MEHA Comparison March 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 68.1B. In comparison, MEHA has a market cap of 1.3M. Regarding current trading prices, COR is priced at $349.00, while MEHA trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 41.95, whereas MEHA's P/E ratio is -3.86. In terms of profitability, COR's ROE is +1.01%, compared to MEHA's ROE of -1.69%. Regarding short-term risk, COR is less volatile compared to MEHA. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check MEHA's competition here
COR vs CVET Comparison March 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 68.1B. In comparison, CVET has a market cap of 0. Regarding current trading prices, COR is priced at $349.00, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 41.95, whereas CVET's P/E ratio is -69.97. In terms of profitability, COR's ROE is +1.01%, compared to CVET's ROE of -0.06%. Regarding short-term risk, COR is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check CVET's competition here